Genmab — August 2016
-
subcu dara vil komme medio 2017
-
men sikke en nyhed fra Sachins side
-
castor pollux data uniformly endorsed as the strongest ever seen
-
EU pricing skal vi ikke læse for meget ind i på længere sigt
-
der kommer feks. price review i tyskland 12 måneder efter launch
-
Bowers spørger ind til om Opdivos failure i fredags får GEN til at overveje IO iinitiativer
-
lyder dog ikke som om JJ har nogle planer om at ændre noget - vil ruller aggressivt ud
-
lyder som om der vil blive rullet et massivt program ud i cancer generelt
-
GEN har kigget intenst på resultaterne fra BMY i fredags
-
over halvdelen af GENs egne
programmer ligger i IO -
jan siger - alle kigger på dara, men vi er VERY excited about duo programmerne
-
immuno oncology
-
tiso rekrutterer robust
-
lyder lidt som om Jan kan have en større deal i baghånden
-
Jan vil ikke fortælle om timing på catorpollux
filing -
...check lige den her - https://clinicaltrials.gov/archive/NCT02519452/2016_08_07/changes
-
maia & cassipeia - recruiting like rockets
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind